Alzheimer's disease and related disorders

Medical Clinics of North America

Volumn 85, Issue 3, 2001, Pages 803-817

  Raskind, Murray A ^b   Peskind, Elaine R ^b  

^a Puget Sound VA Health Care System   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CONJUGATED ESTROGEN; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; NEFAZODONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; PREDNISONE; PROPRANOLOL; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; LEWY BODY; LIVER TOXICITY; NURSING HOME; PATHOPHYSIOLOGY; PRESENILE DEMENTIA; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SENILE DEMENTIA; SUBSTANTIA NIGRA;

EID: 0035030267     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70341-2     Document Type: Article

References (66)

1. The value of chemotherapy in senile mental disturbances
2. A randomized controlled trial of prednisone in Alzheimer's disease
3. About a peculiar disease of the cerebral cortex (1907 article translated by L Jarvik and G Greenson)
4. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study
5. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
6. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients
7. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease
8. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects
9. Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine
10. Effort and cognition in depression
11. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
12. Cholinesterase inhibitors: A new class of psychotropic compounds
13. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
14. Selective loss of central cholinergic neurons in Alzheimer's disease
15. Physostigmine: Effects on cognition and affect in normal subjects
16. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease
17. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
18. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
19. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported
20. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients
21. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
22. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
23. Dementia with Lewy bodies: Response of delirium-like features to donepezil
24. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
25. Newer psychotropic medication use in nursing home residents
26. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group
27. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
28. A randomized, placebo-controlled, double-blind, clinical trial of sertraline in the treatment of major depression complicating Alzheimer disease: Initial results from the DIADS study
29. Mental and behavioral disturbances in dementia: Findings from the Cache County study on memory in aging
30. Use of antidepressants among elderly subjects: Trends and contributing factors
31. Brain inflammation in Alzheimer's disease and the therapeutic implications
32. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
33. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
34. Clinical diagnosis of Alzheimer's disease: A report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
35. Clinical efficacy of donepezil on cognitive functions and psychotic manifestations of Lewy body dementia
36. Factors contributing to nursing home admission because of disruptive behavior
37. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A 1-year randomized controlled trial
38. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
39. Functional status and cognitive impairment in Alzheimer's patients with and without depression
40. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology
41. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
42. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine
43. Loxapine in psychogeriatrics: A placebo- and standard-controlled clinical investigation
44. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome
45. Alzheimer's disease: Treatment of noncognitive behavioral abnormalities
46. Galantamine in AD - A 6-month randomized, placebo-controlled trial with a 6-month extension
47. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression
48. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
49. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial
50. A new rating scale for Alzheimer's disease
51. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
52. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study
53. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
54. Meta-analysis of controlled pharmacologic trials
55. The origins of Alzheimer disease: A is for amyloid
56. A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease
57. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
58. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease
59. Haloperidol in the psychiatric disorders of old age
60. Pharmacologic modelling of Alzheimer's disease
61. A 5-month, randomized, placebo-controlled trial of galantamine in AD
62. Behavioral treatment of depression in dementia patients: A controlled clinical trial
63. Imipramine in the treatment of depressed Alzheimer's patients: Impact on cognition
64. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic acid protease BACE
65. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis